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Oxytocin receptors (OTR) have been described in a number of tumours of different origin, and represent a new target for specific
radiolabelled oxytocin (OT) analogues in cancer diagnosis and therapy. By linking the DOTA chelating agent to position 8 of the
deamino derivative of Lys
8-vasotocin (dLVT), we obtained a new compound (DOTA-dLVT) with the following characteristics: (1) it
forms a monomeric and stable compound that binds to OTR with an affinity comparable to that of the endogenous OT ligand; (2) it
is characterised by a very good selectivity profile for the human OTR, with a low affinity binding to the closely related V1a, V1b and
V2 vasopressin receptor subtypes; (3) it induces rapid and persistent receptor internalisation and (4) when radiolabelled, [
111In]-
DOTA-dLVT is efficiently and selectively taken up by OTR-positive tumours grown in mice. These features makes radiolabelled
DOTA-dLVT a very good candidate for the radiotargeting of OTR-expressing tumours.
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The observation that a variety of tumours overexpress natural
peptide receptors has served as the molecular basis for the clinical
use of radiolabelled peptides in peptide receptor radionuclide
therapy (PRRT) (de Jong and Krenning, 2002), a strategy that has
already proved to be successful in detecting and treating
somatostatin receptor-positive tumours using radioactive soma-
tostatin or its analogues (Froidevaux and Eberle, 2002). In these
tumours, the heavy deposition of radioactive metals such as [
111In]
and [
90Y], which leads to valuable radiodetection and radio-
therapeutic effects, was achieved using the 1,4,7,10-tetraazacyclo-
dodecane-N,N0,N00,N000-tetraacetic acid (DOTA) chelating agent
irreversibly bound to a free amino group of somatostatin or its
analogues (Merlo et al, 1999).
In order to apply PRRT to tumours lacking somatostatin
receptors, other natural peptides need to be investigated. The
oxytocin (OT) hypothalamic nonapeptide binds to various tumour
types via the oxytocin receptor (OTR), a member of the seven
transmembrane spanning family of G-protein-coupled receptors
(Kimura et al, 1992; Gimpl and Fahrenholz, 2001). The tumoral
expression of OTRs was first described in human breast cancer cell
lines (Cassoni et al, 1994) and a large percentage of primary breast
cancers (Bussolati et al, 1996). OTRs have recently also been
detected in tumours of the nervous system such as neuroblastomas
and glioblastomas (Cassoni et al, 1998), osteosarcomas (Novak
et al, 2000), chorioncarcinomas (Cassoni et al, 2001), small cell
lung carcinomas (Pequeux et al, 2002) and Kaposi sarcomas
(Cassoni et al, 2002). It can therefore be hypothesised that suitable
OT analogues appropriately labelled with a radionuclide may be
useful in the diagnosis and treatment of a number of tumours
arising from different tissues. Furthermore, it has also recently
been shown that the human OTR in breast cancers is present in a
cluster of overexpressed genes related to intrinsic and acquired
doxorubicin resistance, and therefore represents a potential
therapeutic target for the management of chemoresistant breast
tumours (Turton et al, 2001).
Interest in OTR expression in such a large range of tumour types
has increased since the recent development of a novel compound
potentially suitable for radioreceptor-mediated diagnosis and
therapy (Bussolati et al, 2001). This compound was obtained by
linking an OT analogue ([Lys8]-vasotocin; LVT) to the DOTA
chelating agent, which is capable of efficaciously binding
111In and
90Y. In LVT, the leucine in position 8 of OT is replaced by a lysine,
thus providing a suitable binding site for the DOTA molecule.
DOTA-LVT has proved to be highly efficient in linking
111In and
transferring the radioactive metal to OTR-positive breast cancer
cells in vitro and in vivo in tumour-bearing mice. However,
because of the reactivity of the free amino group of cysteine in
position 1 of LVT, polymeric complexes were formed during the
process of DOTA conjugation, and the final peptide mixture had
low binding affinity for the human OTR (from 10
 9 to 10
 7 M).
The aim of the present study was to develop an improved
radiotracer characterised by high affinity and specificity for OTR-
expressing tumours. To this end, we used a deaminated LVT at
position 1 (dLVT) (Rimpler, 1971) for the synthesis of a
monomeric radiotracer ([
111In]-DOTA-dLVT). This new radio-
tracer not only retained high and specific affinity for OTR and Received 3 March 2003; revised 15 May 2003; accepted 17 June 2003
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sOTR-positive cells in vitro and in vivo, but was also efficiently
taken up by OTR-positive tumours in vivo.[
111In]-DOTA-dLVT
thus represents a potentially powerful new reagent for the imaging
and treatment of OTR-positive tumours.
MATERIALS AND METHODS
Reagents
DOTA,4H2O (MW of the dehydrated form: 404.4) 4H2O was
purchased from Macrocyclics (Richardson, TX, USA), OT, LVT
(MW 1022.2) (Boissonnas and Huguenin, 1960) and dLVT (MW
1007.2) (Rimpler, 1971) were resynthesised as previously described
(Terrillon et al, 2002).
111In Cl3 was obtained from Mallinckrodt
Medical (Petten, The Netherlands); [
3H]OT (35–45Cimmol
 1)
and [
3H]AVP (35–45Cimmol
 1) were from NEN Life Science
Products (Boston, USA); the other chemicals were purchased from
Sigma (St Louis, MO, USA).
Plan of the experiments
To prove the efficient binding of the radioactive OT analogue to
OTR-positive tumour cells, we first had to link the DOTA chelating
agent to dLVT and show that the resulting compound (DOTA-
dLVT) was monomeric and still retained affinity for OTR. We then
radiolabelled DOTA-dLVT with
111In and tested the binding of
[
111In]-DOTA-dLVT to OTR-positive cells and tumours in vitro
and in vivo.
Conjugation of DOTA to dLVT
The COOH group of DOTA was activated by means of a
carbodiimide reagent (Buckley and Searle, 1984). Briefly, DOTA
was dissolved in anhydrous dimethyl sulphoxide (DMSO) at 801C
and the solution was allowed to cool to room temperature under
an argon atmosphere. A solution of N-hydroxy-2,5-pyrrolidine-
dione (N-hydroxysuccinimide; NHS) in DMSO was added drop-
wise to the stirring solution of DOTA, followed by the dropwise
addition of N,N0-dicyclohexylcarbodiimide (DCC) in DMSO. The
DOTA:NHS:DCC molar ratio was 1:1.4:0.8. The mixture was
allowed to react overnight with stirring, and was then filtered to
remove the by-product dicyclohexylurea. 1,4,7,10-tetraazacyclodo-
decane-N,N0,N00,N000-tetraacetic acid was conjugated to dLVT at a
molar ratio of 50:1 by adding an adequate volume of DOTA-
activated ester solution to dLVT dissolved in 0.1 M phosphate
buffer (pH 8.0). After an overnight reaction, the expected
conjugate (Figure 1) was purified using a reversed-phase column
(Resource RPC 1ml, particle size 15mm; Amersham Pharmacia
Biotech, Uppsala, Sweden) in an FPLC system (LCC-501 Plus
controller, Pharmacia Biotech) coupled with a UV detector (LKB-
UV-MII, Pharmacia Biotech, l¼280nm) and a radiodetector
(Flow Scintillation Analyser, Radiomatic 150 TR, Packard,
Meriden, CT, USA). A linear gradient method was applied using
a solution of distilled water with 0.1% TFA (solvent A) and
methanol (solvent B). The eluents were delivered at a flow of
3mlmin
 1 starting from 0% of solvent A to 100% of solvent B over
37min. In this system, dLVT had a retention time of 9min but,
after the conjugation, only one peak appeared after about 12min.
Unreacted DOTA and the reaction by-products were eluted in the
first minute together with the solvent front (Figure 2A). The
required compound DOTA-dLVT was recovered by means of an
integrated fraction collector (Frac-100, Pharmacia Biotech), and
subsequently analysed by means of a MALDI-TOF mass spectro-
metry (as was the unconjugated dLVT). The mass spectra were
recorded on a Voyager-STR spectrometer with delayed extraction
(PerSeptive Biosystems, Foster City, CA 94404, USA) using a-
cyano-4-hydroxycinnamic acid as matrix (Figure 2B).
Radiolabelling of DOTA-dLVT with
111In
After FPLC purification, DOTA-dLVT was concentrated under
argon, and then 37MBq of
111InCl3, prebuffered with 0.1 M acetic
acid–Na acetate buffer (pH 5.5), was added to 10mg of DOTA-
dLVT (corresponding to 0.007mmol) and heated at 901C for
30min. The radiolabelling yield was checked by FPLC as above. A
specific activity of 5.3GBqmmol
 1 of DOTA-dLVT was obtained
with routine radiochemical yields of more than 95%.
Binding studies on transfected cells
To determine the LVT, dLVT and DOTA-dLVT affinity constants
in comparison with OT, heterologous competition experiments
were performed on membranes prepared from monkey kidney
COS7 cells transiently transfected by means of electroporation with
human OTR, V1a, V2 and V1b cDNAs as previously described
(Chini et al, 1995a). Briefly, the transfected cells were homogenised
with a Dounce glass apparatus, washed twice, and resuspended in
binding buffer (50mM Tris HCl, 5mM MgCl, pH 7.4). Between 5
and 10mg of membrane proteins were incubated with a fixed
concentration of [
3H]OT (1–2nM) for 30min at 301C in the
presence of increasing concentrations of unlabelled peptides.
Nonspecific binding was determined in the presence of 1mM OT.
Bound and free radioactivity were separated by filtration over
Whatman GF/C filters presoaked in 10mgml
 1 BSA. The binding
isotherms were analysed using GraphPad Prism.
Internalisation assays
HEK293 cells stably transfected with the human OTR fused to
EGFP were grown in six-well dishes, washed twice in serum-free
medium, and left to equilibrate for 30min at 371C. Peptides were
then added at a final concentration of 10
 6 M. At fixed time
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Figure 1 Structure of conjugate DOTA-dLVT. Owing to the lack of the
Cys
1 amino group, the DOTA moiety is selectively linked to the only
available e-NH2 of Lys
8.
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sintervals (5, 15, 30 and 60min), the cells were washed twice with
10mM sodium phosphate buffer, pH 7.4, containing 150mM NaCl
(LS buffer), fixed for 20min at room temperature with 4% (wv
 1)
paraformaldehyde, and mounted on glass slides with 90% (vv
 1)
glycerol in PBS. The slides were observed under an MRC1024
BioRad confocal microscope.
Binding studies on tumour cells
Human breast carcinoma (MCF7), glioblastoma (MOG-U-V-W)
and the KATO human gastric carcinoma cell lines were purchased
from ATCC (Manassas, VA, USA). The mammary carcinoma cell
line TS/A growing in Balb/c mice was a gift from Professor Guido
Forni, University of Turin, Italy. All of the cells were grown as
monolayers in RPMI medium (Gibco, Paisley, Scotland) with 10%
fetal calf serum (Gibco) in 25cm
2T flasks in a 5% CO2 humidified
atmosphere at 371C. Previous experiments have shown that MCF7,
MOG-U-V-W and TS/A cells are OTR positive (Cassoni et al, 1994,
1998); the KATO cells acted as an OTR-negative control.
The binding experiments were performed on intact cells. Briefly,
20 10
5 cells suspended in 100ml of culture medium were
incubated for 30min at 41C in the presence of [
111In]-DOTA-
dLVT 1mM. The cell suspension was centrifuged for 5min at
2000g, and the pellet was washed and resuspended in fresh
medium. The centrifugation and cell washing were repeated twice.
The amount of radiolabelling was evaluated by measuring cell-
bound radioactivity (cpm/10
5 cells) using a Packard auto-gamma
counter.
Binding specificity was determined by evaluating radioactive
displacement. Briefly, the cell suspension was incubated for 5min
in the presence of LVT, dLVT or OT 100mM and 1mM, or in the
presence of unrelated peptides (somatostatin 100nM and 1mM, and
hexarelin 1mM) followed by 20min of incubation with 1mM [
111In]-
DOTA-dLVT. The cells were then centrifuged and washed twice as
described above. The activity of the two different agonists and the
unrelated peptides in competing with the radioligand was
evaluated by measuring cell-bound radioactivity. All of the
experiments were performed in triplicate. The statistical analysis
was carried out using ANOVA, with a significance cutoff point of
0.05.
In vivo studies in mice
To determine the amount and specificity of the receptor-mediated
uptake of [
111In]-DOTA-dLVT in tumours, we used an experi-
mental model of OTRþ TS/A tumours growing in Balb/c mice. A
total of 10 female Balb/c mice weighing 25g were subcutaneously
injected with TS/A mammary carcinoma (0.3 10
6 in 0.2ml of
medium). After 20 days, when the growing tumour had reached
about 2cm in diameter, five mice were intravenously administered
50mg of cold OT 30min before the radiotracer and the other five
were not. Mice were injected in the tail vein with [
111In]-DOTA-
dLVT (average activity: 74kBq) and killed 5h later. The organs
were collected, washed, weighed and their radioactivity was
measured in a gamma-ray detector with well-counter geometry
(Silena, Milan, Italy) together with standards of the injection
mixture. Activity was expressed as the percentage of the injected
dose (%ID)g
 1 of tissue, and the uptake ratios of tumour, blood,
kidney and liver were calculated.
RESULTS
Preparation of DOTA-dLVT and radiolabelling
dLVT (Rimpler, 1971) is characterised by the presence of only one
free amino group at position 8. As described above, an activated
ester of DOTA obtained via the NHS/DCC system was reacted
overnight with dLVT. After purification by means of a reversed-
phase column in an FPLC system, we obtained only one peak
corresponding to the desired compound: the peak of the
unconjugated dLVT (9min) disappeared after conjugation, and
another peak was detected at 12min (Figure 2A). MALDI-TOF
analysis confirmed that the desired dLVT and DOTA-dLVT
structures had been successfully obtained (dLVT, [MþH]
þ
1008.5; DOTA-dLVT, [MþH]
þ 1393.7; Figure 2B). Radiochemical
yields of routinely more than 95% led to [
111In]-DOTA-dLVT with
a specific activity of 5.3GBqmmol
 1.
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Figure 2 Panel (A): FPLC profile of dLVT and DOTA-dLVT
(l¼280nm, AUFS¼0.1 for both chromatographic runs). The starting
peptide dLVT had a retention time of 9min (minor peaks are due to
pressure fluctuations). After DOTA conjugation, the DOTA-dLVT peak
was detected after 12min. Panel (B): MALDI-TOF analysis of dLVT and
DOTA-dLVT after purification. Mass spectra of the two compounds show
that conjugation has successfully taken place, giving rise to the desired
product DOTA-dLVT. The second peak in the dLVT spectra is due to the
presence of some residual Na
þ ions after sample desalting ([MþNa]
þ).
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sAffinity of LVT, dLVT and DOTA-dLVT for human OT
receptors
LVT, dLVT and DOTA-dLVT affinities for the human OTR were
determined by means of heterologous competition experiments on
membranes prepared from transiently transfected COS7 cells using
[
3H]-OT as radioligand. As shown in Table 1, unlabelled LVT,
dLVT and DOTA-dLVT inhibited [
3H]-OT binding with very
similar Ki values. As shown in Figure 3A, the OT and DOTA-dLVT
displacement curves were parallel and their slopes were not
significantly different.
[
111In]-DOTA-dLVT affinity for human OTR was also measured
on membranes prepared from transiently transfected COS7 cells
by means of saturation binding assays. As shown in Figure 3B,
the binding of [
111In]-DOTA-dLVT was saturable with a
calculated Kd of 4.5nM, which was very similar to the Ki value
of unlabelled DOTA-dLVT calculated from the competition
experiments.
Our binding experiments therefore indicated that the addition of
a single DOTA-group at position 8 of dLVT brought about a 2–3-
fold enhancement of affinity for the hOTR. Furthermore, the
binding properties of DOTA-dLVT remained unchanged after
labelling with [
111In].
Receptor selectivity
OT/AVP analogues bind to and activate (albeit with different
affinities and efficacies) all members of the OT/AVP receptor
family, which includes the OTR and the three vasopressin receptor
subtypes V1a, V1b and V2 (Peter et al, 1995; Chini et al, 1995b;
Barberis et al, 1999). When developing a specific OTR analogue, it
is therefore essential to check its binding properties not only on
the human OTR, but also on the V1a, V1b and V2 subtypes. To this
end, receptor specificity was analysed by comparing the affinities
of LVT, dLVT and DOTA-dLVT in cells transfected with all of the
members of the OT/AVP receptor family. As shown in Table 1, all
three compounds preferentially bound the human OTR, the only
receptor subtype capable of binding them with nanomolar affinity.
The V1a and V1b receptors showed a 10-fold lower affinity for
LVT and dLVT, and the V2 receptor bound them only at
micromolar concentrations. Interestingly, OTR selectivity further
increased with the addition of the DOTA group. As shown in
Table 1 and Figure 3C, all of the vasopressin subtypes challenged
with DOTA-dLVT showed at least a 300-fold decrease in binding
affinity. These data indicate that DOTA-dLVT not only binds the
human OTR with very high affinity, but also exhibits a strikingly
high selectivity for the human OTR relative to the vasopressin V1a,
V1b and V2 receptor subtypes.
Peptide-induced receptor internalisation
To assess whether LVT, dLVT and DOTA-dLVT behave like OT to
induce receptor internalisation, we applied them to HEK293 cells
stably expressing a human OTR C-terminally tagged with the green
fluorescent protein EGFP (Guzzi et al, 2002; Rimoldi et al, 2003).
As shown in Figure 4, under basal conditions, the fluorescent
receptor is mainly present at the cell surface. However, punctate
Table 1 Peptides inhibition constants (Ki in nM)
Human OTR Human V1a Human V1b Human V2
LVT 2.4070.425 30.874.2 24.977.3 25937625
dLVT 3.8870.585 35.576.2 71.772.0 37377400
DOTA-dLVT 1.2170.199 370758 6407177 35627280
Binding of LVT-derived peptides to human OT/AVP receptor subtypes. Competition
experiments were performed using membrane preparations of COS7 cells transiently
transfected with the wild-type human OTR, and V1a, V1b and V2 receptors. The Ki
values for the human OTR were obtained by displacement of [
3H]-OT; the Ki values
for the human V1a, V1b and V2 receptors were obtained by displacement of [
3H]-
AVP. The values are the mean values7s.e. of three different experiments each
performed in triplicate.
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Figure 3 Binding of LVT-derived peptides to human OT/AVP receptor
subtypes. (A) Comparison of OT and DOTA-dLVT affinity for the human
OTR. Competition experiments were performed using membrane
preparations of COS7 cells transiently transfected with the wild-type
OTR. [
3H]-OT was used at a concentration of 1–2nM, and nonspecific
binding was determined in the presence of 100mM OT. Data are
expressed as the percentage of bound [
3H]-OT in the absence of cold
competitor. The curves are representative of three independent assays
performed in triplicate. (B)[
111In]-DOTA-dLVT saturation binding assay.
The affinity of [
111In]-DOTA-dLVT for the human OTR was measured by
incubating increasing amounts of labelled peptide to membrane prepara-
tions of COS7 cells transiently transfected with the wild-type OTR. The
curve is representative of two independent assays performed in triplicate.
(C) Receptor selectivity profile of DOTA-dLVT. Competition experiments
were performed using membrane preparations of COS7 cells transiently
transfected with the wild-type human OTR, and V1a, V1b and V2
receptors. The membrane preparations of OTR-expressing cells were
incubated in the presence of a constant amount of
3[H]OT (1–2nM), and
nonspecific binding was determined in the presence of 100mM OT. The
membrane preparations of cells expressing V1a, V1b and V2 receptors
were incubated in the presence of a constant amount of
3[H]AVP (2–
4n M), and nonspecific binding was determined in the presence of 100mM
AVP. The data are expressed as percentages of bound [
3H]-ligand in the
absence of cold competitor. Each curve is the mean of triplicate
determinations of a single representative experiment.
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sfluorescence (presumably associated with endocytotic vesicles)
could be seen as early as 5min after the application of LVT, dLVT
and DOTA-dLVT. After 30 and 60min, the fluorescent patches
appeared to be mainly localised in intracellular compartments.
These data indicate that DOTA-dLVT is capable of inducing a
persistent internalisation of the human OTR.
[
111In]-DOTA-dLVT binding to OTRþ and OTR  tumour
cells
The ability of DOTA-dLVT to bind to OTR expressed in cancer
cells was investigated by means of a 30min incubation with
[
111In]-DOTA-dLVT, after which the presence of specific radi-
olabelling was observed in all three OTR-positive cell lines (MCF7,
TS/A and MOG-U-V-W), but was negligible in the OTR-negative
HT29 cell line. Expressed as cpm/10
5cells, the amount of labelling
was 1201776 for MCF7, 7120724 for TS/A and 1523761 for
MOG-U-V-W, and only 8076 for KATO. The specificity of the
binding was proved by means of displacement with cold
radioligands: more than 92% of the specific [
111In]-DOTA-
dLVT binding in OTR-positive cells was displaced by 5min
of preincubation with 100mM and 1mM nonradioactive OT or
LVT.
Preclinical study in animals bearing OTRþ tumours
Biodistribution studies showed that [
111In]-DOTA-dLVT was
capable of binding in vivo to OTR in TS/A tumours (Table 2).
The specific uptake in tumour (0.23%IDg
 1) was higher than that
in blood (0.03%IDg
 1) or liver (0.16%IDg
 1), thus leading to
tumour/blood and tumour/liver uptake ratios of, respectively, 7.58
and 1.42. As expected, kidney showed the highest uptake
(3.56%IDg
 1). When the TS/A tumours were blocked with 50mg
of cold OT, there was a three-fold decrease in the uptake of [
111In]-
DOTA-dLVT.
DISCUSSION
We report here the synthesis and pharmacological properties of a
new receptor-mediated radiotracing compound ([
111In]DOTA-
dLVT), specific for OTR-expressing cells and tumours.
As a starting compound, we used dLVT (Rimpler, 1971), an OT
analogue with only one potential binding site for a chelating agent:
the free e-NH2 group of the lysine residue in position 8. The lysine
e-NH2 group has been widely used to link chemical reagents to
peptides (Meares et al, 1984; Terrillon et al, 2002). We used a slight
molar excess of DOTA to NHS/DCC in order to activate only one
carboxyl group and prevent DOTA from bridging two or more
dLVT molecules. After linking DOTA to dLVT, no polymeric
compounds were detected by MALDI-TOF mass spectrometry
analysis, thus confirming the 1:1 binding of the chelating agent to
the only active binding site.
Purified DOTA-dLVT showed a very high (nanomolar) affinity
for the human OTR, analogous to that exhibited when the
fluoresceinyl (Flu) group was attached to the Lys8 residue in
dLVT to give d[Lys
8(5/6 C-Flu)]VT (Terrillon et al, 2002).
Deamination of OT and its analogues had been shown to enhance
biological activity in vivo by making the peptide less susceptible to
aminopeptidase (Golubow and du Vigneaud, 1963).
Since OT/vasopressin analogues bind to and activate four
different receptor subtypes (OTR, V1a, V1b and V2) (Chini et al,
1995b; Peter et al, 1995; Barberis et al, 1999), peptides of potential
clinical use should be checked for their receptor selectivity. Our
competition experiments on receptor-rich membrane preparations
showed that dLVT binds to human OTR, V1a, V1b and V2 with a
pharmacological profile that is very similar to that of OT.
Interestingly, the addition of the DOTA moiety in position 8 of
dLVT brought about a 2–3-fold increase in affinity for the human
OTR, compared to both OT and dLVT, while greatly reducing its
affinity for the V1a, V1b and V2 receptor subtypes. These findings
closely agree with those of a previous study based on molecular
modelling and site-directed mutagenesis, which indicated that the
interactions of the residue in position 8 are crucial in determining
the high affinity of OT/AVP peptides for the vasopressin receptor
subtypes (Chini et al, 1995a), but are much less important for the
human OTR (Chini et al, 1995b). The striking increase in receptor
selectivity of DOTA-dLVT for the human OTR is particularly
relevant because it should reduce the likelihood of side effects
due to peptide binding to the V1a, V1b and V2 vasopressin
receptors.
As a chelator, DOTA is sufficiently flexible to be efficiently
radiolabelled with not only diagnostic g-ray emitters such as
111In,
Peptide-induced receptor internalisation
BAS 5 min 30 min 60 min
LVT
dLVT
DOTA-dLVT
Figure 4 Laser-scanning confocal microscopy analysis of peptide-
induced receptor internalisation. Receptor internalisation was investigated
in HEK293 cells stably transfected with the human OTR bearing the EGFP
fused at its C-terminus. The cells were grown on coverslips and incubated
in serum-free medium for 30min (Bas), after which the peptides were
added at a final concentration of 10
 6 M and the coverslips were fixed at 1,
5, 15, 30 and 60min.
Table 2 Preclinical study of animals bearing TS/A tumours
Group I [
111In]-DOTA-dLVT
and cold OT
Group II [
111In]-
DOTA-dLVT only
Tumour (%IDg
 1) 0.079 0.230
Blood (%IDg
 1) 0.017 0.030
Kidney (%IDg
 1) 1.693 3.559
Liver (%IDg
 1) 0.075 0.162
Tumour/blood ratio 4.54 7.58
Tumour/kidney ratio 0.05 0.06
Tumour/liver ratio 1.05 1.42
Balb/c mice bearing TS tumours positive for the human OTR were intravenously
injected with [
111In]-DOTA-dLVT. Five mice were injected with 50mgo fc o l dO T
30min before receiving the radiotracer (Group I); five mice received only the
radiotracer (Group II). A 20-fold dilution of the injected dose (average activity
74kBq) was used as a standard for the total administered activity. Activity is
expressed as a percentage of injected dose (%ID)g
 1 of tissue, and ratios of uptake
between tumour, blood, kidney and liver were calculated. The data are averages of
five replicates; the activity remaining in the tail was also considered and subtracted
from the total activity for the calculations.
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  radionuclides (e.g.
90Y, Ebmax¼
2.28MeV, range 1.1 10
 2m, and
177Lu, Ebmax¼0.50MeV, range
2 10
 3m) as it has already been successfully used to convey them
to human tumours in association with somatostatin analogues
(Otte et al, 1998; Paganelli et al, 1999). We found that DOTA-dLVT
was very efficiently labelled with
111In and we are currently
investigating its labelling with therapeutic radionuclides.
To be used in therapeutic applications, a radiopeptide should
not only have a binding profile of high affinity and selectivity, but
must also be characterized by persistent presence at tumour sites.
In the case of analogues that bind to membrane receptors, one very
useful property is their ability to enter cells as a result of peptide-
induced receptor internalisation, which would have a number of
positive effects: the radionuclide would remain longer at the
tumour site and there would not be a decrease in surface binding
due to peptide dilution. Furthermore, the internalised peptide
would be closer to the DNA (the final target of the cytotoxicity
exerted by radionuclides such as [
90Y]) and, as [
90Y] emits short-
range Auger electrons, the surrounding cells would remain
unaffected. Using a fluorescent reporter (EGFP) constitutively
linked to OTR and stably transfected in HEK293 cells (Rimoldi
et al, 2003), we traced the fate of the receptor after LVT, dLVT and
DOTA-dLVT binding. All of these compounds induced a rapid and
persistent receptor internalisation similar to that induced by
oxytocin (Guzzi et al, 2002). Given that the binding of the
radioactive metal to the chelating agent does not affect its affinity
and is unlikely to affect the internalisation of the ligand–receptor
complex, the tracer will probably remain inside the target and thus
ensure an enhanced tumour/blood ratio allowing efficient imaging
and cytotoxicity. Our in vitro and in vivo murine experiments
showed that
111In-DOTA-dLVT selectively binds to OTR-positive
cells and tumours, and is thus a potentially powerful reagent for
the imaging and treatment of OTR-positive cancers. As OTRs are
expressed in various tumours in which conventional chemo- and
hormonal therapy may slow disease progression but are not
curative (particularly brain glioblastomas and metastatic breast
cancers), radiolabelled DOTA-dLVT offers an exciting and entirely
new approach to the treatment of such life-threatening malig-
nancies.
ACKNOWLEDGEMENTS
This work was supported by grants from the special project
‘Oncology’ Compagnia San Paolo/FIRMS (Turin, Italy), from the
Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan),
from the University of Turin, and from the NIH (Grant GM-25280
MM). We thank Dr Stoytcho Stoev for the resynthesis of dLVT in
the Manning laboratory.
REFERENCES
Barberis C, Morin D, Durroux T, Mouillac B, Guillon G,
Hibert M, Tribollet E, Manning M (1999) Molecular pharmacology of
AVP and OT receptors and therapeutic potential. Drug News Perspect 12:
279–292
Boissonnas RA, Huguenin RL (1960) Synthe `se de la Lys8-oxytocine (lysine-
vasotocine) et nouvelle synthe `se de la lysine-vasopressine. Helv Chem
Acta 43: 182–190
Buckley RG, Searle F (1984) An efficient method for labeling antibodies
with 111In. FEBS Lett 166: 202–204
Bussolati G, Cassoni P, Ghisolfi G, Negro F, Sapino A (1996) Immunolo-
calization and gene expression of oxytocin receptors in carcinomas and
non-neoplastic tissues of the breast. Am J Pathol 148: 1895–1903
Bussolati G, Chinol M, Chini B, Nacca A, Cassoni P, Paganelli G (2001)
111In-labeled 1,4,7,10-tetraazacyclododecane-N,N0,N00,N000-tetraacetic
acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin recep-
tor-expressing tumors. Cancer Res 61: 4393–4397
Cassoni P, Sapino A, Negro F, Bussolati G (1994) Oxytocin inhibits
proliferation of human breast cancer cell lines. Virchows Arch 425:
467–472
Cassoni P, Sapino A, Stella A, Fortunati N, Bussolati G (1998) Presence and
significance of oxytocin receptors in human neuroblastomas and glial
tumors. Int J Cancer 77: 695–700
Cassoni P, Sapino A, Munaron L, Deaglio S, Chini B, Graziani A, Ahmed A,
Bussolati G (2001) Activation of functional oxytocin receptors stimulates
cell proliferation in human trophoblast and choriocarcinoma cell lines.
Endocrinology 142: 1130–1136
Cassoni P, Sapino A, Deaglio S, Bussolati B, Volante M, Munaron L, Albini
A, Torrisi A, Bussolati G (2002) Oxytocin is a growth factor for Kaposi’s
sarcoma cells: evidence of endocrine-immunological cross-talk. Cancer
Res 62: 2406–2413
Chini B, Mouillac B, Ala Y, Balestre M, Trumpp-Kallmeyer S, Hoflack J,
Elands J, Hibert M, Manning M, Jard S, Barberis C (1995a) Tyr115 is the
key residue for determining receptor selectivity in the V1a vasopressin
receptor. EMBO J 14: 2176–2182
Chini B, Mouillac B, Ala Y, Balestre MN, Cotte N, Trumpp-Kallmeyer S,
Hoflack J, Elands J, Hibert M, Manning M et al. (1995b) Molecular basis
for agonist selectivity in the vasopressin/oxytocin receptor family. Adv
Exp Med Biol 395: 321–328
de Jong M, Krenning E (2002) New advances in peptide receptor
radionuclide therapy. J Nucl Med 43: 617–620
Froidevaux S, Eberle AN (2002) Somatostatin analogs and radiopeptides in
cancer therapy. Biopolymers 66: 161–183
Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure,
function, and regulation. Physiol Rev 81: 629–683
Golubow J, du Vigneaud V (1963) Comparison of susceptibility of oxytocin
and desamino-oxytocin to inactivation by leucine aminopeptidase and a-
chymotrypsin. Proc Soc exp Biol 112: 218–219
Guzzi F, Zanchetta D, Cassoni P, Guzzi V, Francolini M, Parenti M, Chini B
(2002) Localisation of the human oxytocin receptor in caveolin-1
enriched domains turns the receptor-mediated inhibition of cell growth
into a proliferative response. Oncogene 21: 1658–1667
Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H (1992)
Structure and expression of human oxytocin receptor. Nature 356:
526–529
Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI,
McTigue M (1984) Conjugation of antibodies with bifunctional chelating
agents: isothiocyanate and bromoacetamide reagents, methods of
analysis, and subsequent addition of metal ions. Anal Biochem 142:
68–78
Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E,
Freitag P, Reubi JC, Muller-Brand J, Gratzl O, Macke HR (1999)
Locoregional regulatory peptide receptor targeting with the diffusible
somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide
(DOTATOC): a pilot study in human gliomas. Clin Cancer Res 5:
1025–1033
Novak JF, Judkins MB, Chernin MI, Cassoni P, Bussolati G, Nitche JA,
Nishimoto SK (2000) A plasmin-derived hexapeptide from the carboxyl
end of osteocalcin counteracts oxytocin-mediated growth inhibition
[corrected] of osteosarcoma cells [published erratum appears in Cancer
Res 2000 Aug 15;60(16):4663]. Cancer Res 60: 3470–3476
Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR
(1998) Yttrium-90-labeled somatostatin-analogue for cancer treatment.
Lancet 351: 417–418
Paganelli G, Zoboli S, Cremonesi M, Macke HR, Chinol M (1999) Receptor-
mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreo-
tide: preliminary report in cancer patients. Cancer Biother Radiopharm
14: 477–483
Pequeux C, Breton C, Hendrick JC, Hagelstein MT, Martens H, Winkler R,
Geenen V, Legros JJ (2002) Oxytocin synthesis and oxytocin receptor
expression by cell lines of human small cell carcinoma of the lung
stimulate tumor growth through autocrine/paracrine signaling. Cancer
Res 62: 4623–4629
Peter J, Burbach H, Adan RA, Lolait SJ, van Leeuwen FW, Mezey E,
Palkovits M, Barberis C (1995) Molecular neurobiology and pharmacol-
[
111In]DOTA-dLVT: a radioligand for OTR-expressing tumours
B Chini et al
935
British Journal of Cancer (2003) 89(5), 930–936 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sogy of the vasopressin/oxytocin receptor family. Cell Mol Neurobiol 15:
573–595
Rimoldi V, Reversi A, Taverna E, Rosa P, Francolini M, Cassoni P, Parenti
M, Chini B (2003) Oxytocin receptor elicits different EGFR/MAPK
activation patterns depending on its localization in caveolin-1 enriched
domains. Oncogene, in press
Rimpler M (1971) [1-Desamino]-lysinvasotocin, ein disulfidpolypeptid mit
oxytocin-wirkkung. Justus Liebigs Ann Chem 745: 8–19
Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T
(2002) Synthesis and characterization of fluorescent antagonists and agonists
for human oxytocin and vasopressin V1a receptors. J Med Chem 45:
2579–2588
T u r t o nN J ,J u d a hD J ,R i l e yJ ,D a v i e sR ,L i p s o nD ,S t y l e sJ A ,S m i t hA G ,G a n t
TW (2001) Gene expression and amplification in breast carcinoma cells
with intrinsic and acquired doxorubicin resistance. Oncogene 20:
1300–1306
[
111In]DOTA-dLVT: a radioligand for OTR-expressing tumours
B Chini et al
936
British Journal of Cancer (2003) 89(5), 930–936 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s